CClinicalTrials.gg
Not yet recruitingNCT06101771Updated Oct 26, 2023

Assessment of Epicardial Fat Thickness in Children With Familial Dyslipidemia

An observational study in Dyslipidemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
42
Ages
1 Month to 18 Years
Sex
All
01

Study summary

Aim of the study: 1- Detect common types of familial dyslipidemia. 2- Significance and relationship between Epicardial fat thickness and familial dyslipidemia.

Read the detailed description

Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Lipids, such as cholesterol or triglycerides, are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation . Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of any of these factors, either from organic or nonorganic causes, can lead to dyslipidemia. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Primary dyslipidemia can be due to familial disorders as well. Autosomal dominant mutations cause most cases of familial hypercholesterolemia in LDL receptors, which causes an elevation in LDL-C levels. Other mutations in the cholesterol pathway have been identified but are less common. Several health behaviors can have effects and increase lipid levels. Examples include tobacco use, physical inactivity, nutrition, and obesity. Specifically, nutrition risk factors include the insufficient consumption of fruits, nuts/seeds, vegetables, or high consumption of saturated fats.

The heart and vessels are surrounded by layers of adipose tissue, which is a complex organ composed of adipocytes, stromal cells, macrophages, and a neuronal network, all nourished by a rich microcirculation . The layers of adipose tissue surrounding the heart can be subdivided into intra- and extrapericardial fat. Their thicknesses and volumes can be quantified by echocardiography and CT or magnetic resonance imaging, respectively.

The term extrapericardial fat defines thoracic adipose tissue external to the parietal pericardium. It originates from primitive thoracic mesenchymal cells and thus derives its blood supply from noncoronary sources. Intrapericardial fat is further subdivided into epicardial and pericardial fat. Anatomically, Epicardial and pericardial adipose tissues are clearly different.

Epicardial fat is located between the outer wall of the myocardium and the visceral layer of pericardium. Epicardial adipose tissue (EAT) is a component of visceral adiposity and mediates cardiac function and atherosclerosis via expression of several bioactive molecules.

EAT is a measure of the adipose tissue between the myocardium and visceral pericardium which can be visualized using transthoracic echocardiogram as a non-invasive assessment of EAT. Some studies have used EAT as a marker for metabolic syndrome; however, it does not have standard utility related to other cardiac syndromes. This fat layer buffers the coronary arteries from cardiac contraction and arterial pulse wave while providing the myocardium with necessary substrate through diffusion of free fatty acids. 4 When there is a surplus of energy, free fatty acids are readily converted into triglycerides and stored in epicardial adipocytes, increasing the volume of the epicardial adipose layer and serving as a triglyceride depot for the myocardium to draw from during periods of higher energy needs. Studies in adults suggest that increased EAT results in greater cytokine production in the fat directly surrounding the coronary vessels, including tumor necrosis factor-αas well as several interleukins. These cytokines contribute to atherosclerosis by increasing lipolysis, increasing inflammation, and causing endothelial dysfunction. Endothelial dysfunction coupled with migration of macrophages, basophils, and other cells further exacerbate plaque formation and eventually causes disruption in the structure of the intima and flow within the lumen.8,9Recent studies suggest that increased EAT is predictive of incident CVD in adults with T1D independent of traditional CVD risk factors such as BMI. Although the majority of studies examining EAT have been conducted in the adult population, EAT has been measured in pediatric studies of obesity and metabolic syndrome.

02

Conditions studied

  • Dyslipidemia

Browse trials for

03

In context

Dyslipidemias

1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.

This study's planned enrollment of 42 is below the median of 600 across 204 observational studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Setting: Tertiary care center ( Assiut University children Hospital) (AUCH) from Sep 2023 to Sep 2025.

Normal weight children more than 1 month and till age of 18 years that attend Assiut University children Hospital with Clinical manifestation:

  1. Non-symptomatic accidentally discovered dyslipidemia.
  2. Steatorrhea.
  3. Fatty liver.

Inclusion criteria

  • Normal weight children more than 1 month and till age of 18 years that attend Assiut University children Hospital with Clinical manifestation:

    1. Non-symptomatic accidentally discovered dyslipidemia.
    2. Steatorrhea.
    3. Fatty liver

Exclusion criteria

Exclusion Criteria:

1- Patients who had poor echo window : chest deformities, chronic lung disease, pericardial and/or pleural effusion on transthoracic echocardiography, and chronic kidney disease were not included in the study.

  1. Congenital heart diseases. 3. Children with liver diseases that cause 2ry dyslipidemia. 4. Children with Diabetes that cause 2ry dyslipidemia
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
42 participants (estimated)
Patient registry
No

Groups and cohorts

  • dyslipidemia

    Normal weight children more than 1 month and till age of 18 years that attend Assiut University children Hospital with Clinical manifestation: 1. Non-symptomatic accidentally discovered dyslipidemia. 2. Steatorrhea. 3. Fatty liver.

    Diagnostic Test: echoCARDIOGRAPHY

Interventions

  • Diagnostic testechoCARDIOGRAPHY

    Assessment of epicardial fat thickness in children with familial dyslipidemia

06

What researchers measure

Primary outcomes

  1. assessment epicardial fat thickness in children with familial dyslipidemia

    All cases included in the study will be evaluated by: 1. - Fasting lipid profile: Total cholesterol, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Triglycerides (TG). (18) 2. - Transthoracic Echocardiography.

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06101771
Lead sponsor
Assiut University
Responsible party
Mina Mamdouh Wahib Tadros (Resident doctor of Pediatrics, Faculty of Medicine, Assiut University, Principal Investigator., Assiut University) — Principal investigator
First posted
Oct 26, 2023
Start date
Dec 20, 2023 (estimated)
Primary completion
Dec 20, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Oct 26, 2023

Study contacts

mina mamdoh Tadros, resident doctor
Contact
do7a.mmdoh@gmail.com
+201286186279
Faisal-Al Khateeb Al Khateeb ahmed, professor of pediatrics
Contact
faisalalkhateeb@aun.edu.eg
+201003858676
Amr Mohamed Kotb, Lecturer of Pediatrics
study director · Assiut University
Mohamed Abou Bakr Sobeih, Lecturer of Pediatrics
study director · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion